Arteris, Inc. (NASDAQ:AIP) is one of the 14 Small Publicly Traded Semiconductor Companies to Invest in Now. On August 25, Northland Securities maintained a Buy rating on Arteris, Inc. (NASDAQ:AIP) with a price target of $16. Previously, on August 5, TD Cowen had also reiterated a Buy rating on Arteris, Inc. (NASDAQ:AIP) and raised the price target from $12 to $15. This decision came after the company reported results for the second quarter of 2025. Analysts Bullish on Arteris (AIP) with Buy Ratings Arte ...

CAMPBELL, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP for accelerating semiconductor creation, today announced that NanoXplore, a provider of radiation-hardened system-on-chip (SoC) FPGA technology, has licensed Arteris’ FlexGen smart NoC IP for its space designs. FlexGen will be used in the development of complex FPGA structures that deliver improved performance, efficiency, and reliability to address mission-critical computing in aerospace applic ...

Arteris, Inc. (NASDAQ:AIP) is one of the 15 Best Robotics Stocks to Buy Under $20. Arteris, Inc. (AIP) Announces Its Membership in the Ultra Accelerator Link (UALink) Consortium On August 26, 2025, Arteris, Inc. (NASDAQ:AIP) announced its membership in the Ultra Accelerator Link (UALink) Consortium, which is developing open standards for high-speed interconnects between AI accelerators. With its network-on-chip (NoC) technology already powering high-bandwidth, low-latency processors, Arteris is well-posi ...

Group 1: Company Overview - Arteris, Inc. is a leading provider of system IP for accelerating semiconductor creation, focusing on high-performance, power-efficient silicon solutions [5] - The company specializes in network-on-chip (NoC) technology, which is utilized by major technology leaders in developing advanced high-bandwidth, low-latency HPC and AI accelerators [1][5] Group 2: Industry Trends - The demand for AI is driving the need for specialized computing and networking solutions, as general-purpose systems are unable to meet the increasing workload demands [2] - Hyperscale data center infrastructures must evolve to support efficient and fast connections, which are essential for AI workloads [2] Group 3: Consortium Membership - Arteris has joined the Ultra Accelerator Link Consortium (UALink), which aims to establish an open ecosystem to enhance innovation and collaboration in AI [1][3] - The UALink Consortium is focused on developing technical specifications for high-speed, scale-up accelerator interconnect technology to improve AI cluster performance [6] Group 4: Strategic Goals - Arteris is committed to advancing next-generation connectivity standards and driving innovation in AI and high-performance computing technologies [4] - The company's involvement in UALink highlights its dedication to ensuring that its network-on-chip capabilities contribute to the development of standards for future AI infrastructure [4]

Group 1: Technology Sector Overview - Information technology is one of the top-performing sectors in 2025, but returns are unevenly distributed across the tech universe [1] - The Magnificent Seven, including major firms like Apple Inc. and Alphabet, have performed in line with the broader market, with the Roundhill Magnificent Seven ETF returning 9.6% compared to 9.3% for the S&P 500 year-to-date [2] Group 2: Indie Semiconductor Inc. - Indie Semiconductor, a specialized semiconductor maker for the automotive industry, has a market cap under $1 billion and reported a non-GAAP gross margin of 49.1% in Q2 2025 [3][4] - The company is preparing to scale production of its 77 GHz radar chipset and has found success with its LXM laser product, which could address a market worth up to $5 billion by 2030 [4] - Five out of six analysts have given indie a Buy rating, with a 12-month stock price forecast of $5.90, indicating a potential upside of 37.85% from the current price of $4.28 [5] Group 3: ACM Research Inc. - ACM Research, which specializes in chipmaking equipment, reported a revenue increase of over 6% year-over-year to over $215 million, driven by sales of its Ultra C WB wet bench tool [7][8] - The company has nearly doubled its long-term revenue forecast for its Chinese business to $2.5 billion, anticipating significant growth in the semiconductor space [8] - ACM shares have risen almost 14% year-to-date, with a consensus price target of $26.33, suggesting further upside potential [9] Group 4: Arteris Inc. - Arteris focuses on on-chip interconnect fabric technology and reported Q2 2025 revenue of $16.5 million, beating expectations despite a GAAP net loss of $9.13 million [10][11] - The company has a market cap under $400 million and is expected to have a significant impact in the AI chip industry, with all three analysts rating its shares as a Buy [12] - Analysts project a 12-month stock price forecast of $15.00 for Arteris, indicating a potential upside of 63.40% from the current price of $9.18 [10]

Financial Data and Key Metrics Changes - The company's turnover increased by 1% to R9.8 billion for the year, with a notable recovery in the second half driven by strong demand and improved operational performance [4][30] - Trading profit declined by 4% to R1.18 billion, recovering from a 17% decline reported at the half-year mark [6][33] - Headline earnings per share increased by 1.5% to 625.6 cents, supported by solid contributions from joint ventures and share repurchase impacts [6][35] Business Line Data and Key Metrics Changes - The Consumer division saw a 6% increase in trading profit, driven by strong performance in personal and home care products, particularly the EpiMax brand [12][41] - The Over-the-Counter (OTC) division's trading profit increased by 5% to R404 million, benefiting from an early flu season and normalized buying patterns [16][43] - The Prescription division's trading profit decreased by 25% to R265 million, although it showed recovery from a 52% decline at the half-year [18][45] - The Hospital division's revenue increased by 6.7% to R2.2 billion, supported by increased demand for renal products and intravenous fluids [22][46] Market Data and Key Metrics Changes - The company reported a gross margin decline to 33%, down from 33.4% the previous year, influenced by a less favorable sales mix and lower production levels at the Wadeville facility [5][32] - The OTC division holds a market share of about 20% and a volume share of almost 30% in South Africa [13] Company Strategy and Development Direction - The company is focusing on integrating the Lundbeck portfolio to strengthen its presence in the central nervous system pharmaceuticals market [19][20] - A commercial agreement with GSK South Africa aims to introduce a pipeline of vaccines, starting with Bexera for meningitis B prevention [20] - The company is investing in infrastructure improvements and regulatory compliance to enhance operational resilience [24][27] Management's Comments on Operating Environment and Future Outlook - Management noted a marked improvement in trading and financial performance in the second half, driven by strong demand and disciplined cost management [4][6] - The regulatory environment remains stable, with updates on codeine-containing medicines and ongoing assessments for orally administered phenylephrine products [7][8] - The company is optimistic about future growth, particularly in the hospital and prescription divisions, despite challenges faced in the past year [18][22] Other Important Information - The company has made significant investments in sustainability initiatives, including waste management and renewable energy projects [25][26] - A ten-year supply and distribution agreement with Medline has been signed to enhance the hospital division's offerings [25] Q&A Session Summary Question: Are there any questions from the conference call? - There were no questions from the conference call or the webcast, indicating a comprehensive overview was provided [49][50]

GROUP ANNUAL RESULTS FOR THE YEAR ENDED 30 JUNE 2025 Andy Hall, CEO & Dorette Neethling, CFO OVERVIEW ANDY HALL, CEO 2 PANADO PRODUCT OF THE YEAR Panado Syrups and Panado Adult effervescent pain relief TRANSFORMATION CHILD HEALTH ADULT PAIN RELIEF 3 PERFORMANCE FY2025 H2 vs H1 TURNOVER +7% TRADING PROFIT +30% TURNOVER +1% R9.8b TRADING PROFIT -4% R1.2b DIVIDEND +2% 280 cents HEPS +1% 626 cents HEPS +36% 4 CONSUMER REVENUE R1 802m +6% TRADING PROFIT R385m +6% 5 OTC REVENUE R2 442m -1% TRADING PROFIT R404m +5 ...

Core Insights - Arteris, Inc. has been awarded the Gold Stevie® Award for Most Innovative Tech Company of the Year at the 22nd Annual International Business Awards® [1][3] - The company's FlexGen smart NoC IP received a Silver Stevie® for Achievement in Technology Innovation, while its Magillem Registers integration automation software earned a Bronze Stevie® for Achievement in Product Innovation [1][3] Company Overview - Arteris is a leading provider of semiconductor system IP, focusing on accelerating the development of chiplet and system-on-chip (SoC) technologies [1][4] - The company's technologies, including NoC interconnect IP and SoC integration automation software, enhance product performance, reduce energy consumption, and shorten time to market [3][4] - Arteris aims to improve total cost of ownership (TCO) and overall economics for semiconductor companies, facilitating innovation in areas such as AI data centers and smart edge applications [3]

Group 1 - The investment community often undervalues enabling technologies that support advanced semiconductor technologies despite the prominence of AI chipmakers [1] - The focus is on identifying asymmetric risk-reward opportunities through quantitative analysis and market intuition [1] - The investment philosophy emphasizes exploiting market anomalies and emerging opportunities while maintaining disciplined risk management [1] Group 2 - Sector coverage includes technology disruptors, undervalued small-cap companies, and those benefiting from long-term structural trends [1] - There is a particular interest in businesses with strong competitive moats, innovative technologies, and capable management teams [1]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $16.5 million, up 13% year over year, at the top end of guidance range [15] - Annual contract value (ACV) plus royalties reached $69.1 million, a 15% year-over-year increase, marking a record high for the company [16] - Remaining Performance Obligations (RPO) at the end of Q2 were $99.3 million, representing a 28% year-over-year increase, also a new high [16] - Non-GAAP gross profit for the quarter was $15 million, with a gross margin of 91% [16] - GAAP gross profit was $14.8 million, with a gross margin of 89% [16] - Non-GAAP operating loss for the quarter was $3.5 million, flat year over year [18] - GAAP operating loss for Q2 was $8.2 million, compared to a loss of $7.4 million in the prior year [18] - Non-GAAP net loss for the quarter was $4.4 million, or diluted net loss per share of $0.11 [19] - GAAP net loss for the quarter was $9.1 million, or diluted net loss per share of $0.22 [19] - Free cash flow was negative $2.8 million for Q2, approximately at the midpoint of guidance range [19] Business Line Data and Key Metrics Changes - Increased adoption of Arteris' technology in enterprise computing and automotive applications, driven by AI computing [8] - Over two dozen FlexGen installations at multiple customers, expected to contribute to revenue over time [9] - Expansion of multi-die solutions announced, supporting chiplet architectures and collaborations with major industry players [10][11] - Introduction of Magellan Packaging, a new software product aimed at automating IP packaging for silicon chiplets [12] Market Data and Key Metrics Changes - The semiconductor industry is shifting from traditional monolithic chips to multi-die or chiplet architectures, particularly driven by AI workloads [10] - Anticipation of a growing number of heterogeneous chiplet projects, with current estimates at about 30 projects out of 600 to 700 SoCs [44] Company Strategy and Development Direction - Focus on strategic investments in R&D and customer support to drive technology innovations and expand market reach [18] - Ongoing development of new silicon system IP technologies and strong relationships with leading electronics companies [12] - Monitoring global economic uncertainty while capitalizing on opportunities for customers to outsource system IP needs [12] Management's Comments on Operating Environment and Future Outlook - Management remains encouraged by strong deal execution, evidenced by a 28% year-over-year growth in RPO [21] - Despite foreign exchange fluctuations impacting operating expenses, the company sees promising signs of accelerated interest from major customers [21] - Guidance for Q3 2025 includes expected ACV plus royalties of $69.5 million to $72.5 million and revenue of $16.8 million to $17.2 million [20] Other Important Information - The company was recognized with the AI Engineering Innovation Award for FlexGen at the AI Breakthrough Awards [9] Q&A Session Summary Question: Details on AMD announcement and scope of partnership - AMD chose Arteris' FlexGen technology for various products, including AI data center chiplets, after extensive evaluation against competitors [26][27] Question: Impact of AMD's decision on internal teams and performance metrics - AMD will continue using its internal cash coherent fabric while augmenting it with Arteris technology for non-coherent applications [36] Question: Customer adoption of FlexGen and support for decision-making - There are over two dozen FlexGen installations, with expectations for sales to begin in the second half of the year [37] Question: Update on heterogeneous chiplet projects - Currently, about 30 heterogeneous chiplet projects are identified, with expectations for growth in the coming years [44]